Clinical Trials Logo

Filter by:
NCT ID: NCT01513460 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Start date: April 2012
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.

NCT ID: NCT01511913 Completed - Clinical trials for Advanced Cutaneous Melanoma

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

IMAGE
Start date: June 3, 2012
Phase:
Study type: Observational

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting

NCT ID: NCT01511692 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Start date: November 2005
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.

NCT ID: NCT01511172 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effect on glycemic control of NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with OHAs (oral hypoglycaemic agents).

NCT ID: NCT01510951 Completed - Psoriasis Clinical Trials

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

Start date: August 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, immunogenicity, and clinical effects of AMG 811 following single subcutaneous dose administration in subjects with moderate to severe psoriasis.

NCT ID: NCT01510769 Completed - Tophaceous Gout Clinical Trials

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

CRYSTAL
Start date: January 2012
Phase: Phase 3
Study type: Interventional

This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat to febuxostat alone in patients with tophaceaous gout.

NCT ID: NCT01510028 Completed - Clinical trials for Metachromatic Leukodystrophy (MLD)

Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)

IDEAMLD
Start date: February 2, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety of ascending doses of HGT-1110 administered by intrathecal (IT) injection for 38 weeks (20 injections) in children with metachromatic leukodystrophy (MLD).

NCT ID: NCT01508806 Completed - Clinical trials for Diabetes Mellitus, Type 2

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Start date: August 2005
Phase: Phase 1
Study type: Interventional

This trial is conducted in Oceania. The aim of this trial is to assess whether dose adjustment is required for patients with renal impairment by investigating the pharmacokinetics of liraglutide in subjects with various degrees of renal impairment.

NCT ID: NCT01508702 Completed - Gout Clinical Trials

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

LIGHT
Start date: January 2012
Phase: Phase 3
Study type: Interventional

This study will assess the serum uric acid lowering effects and safety of lesinurad compared to placebo in patients who are intolerant or have a contraindication to allopurinol or febuxostat.

NCT ID: NCT01507077 Completed - Obesity Clinical Trials

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Start date: December 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).